CEL-SCI (CVM) Receives Approval To Expand Its Immunotherapy Phase 3 Head And Neck Cancer Trial Into The United Kingdom
6/2/2014 10:36:47 AM
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT:CVM) today announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted regulatory approval to begin the Company’s Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in the United Kingdom (UK). The UK becomes the 13th country to join the trial. Several hospitals and medical clinics in the UK are expected to participate in the Phase III trial for the treatment of head and neck cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by